|Datasheet||Specific References||Reviews||Related Products||Protocols|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Cynomolgus monkey TNFSF8 Gene cDNA Clone (full-length ORF Clone), expression ready, FLAG-tagged||CG90091-G-F|
|Cynomolgus monkey TNFSF8 Gene cDNA Clone (full-length ORF Clone), expression ready, His-tagged||CG90091-G-H|
|Cynomolgus monkey TNFSF8 Gene cDNA Clone (full-length ORF Clone), expression ready, Myc-tagged||CG90091-G-M|
|Cynomolgus monkey TNFSF8 Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||CG90091-G-N|
|Cynomolgus monkey TNFSF8 Gene cDNA Clone (full-length ORF Clone), expression ready, HA-tagged||CG90091-G-Y|
CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.